OBJECTIVE: Macrophages exhibit distinct phenotypes and are dysregulated in a model of iatrogenic laryngotracheal stenosis (iLTS). Increased populations of alternatively activated or M2 macrophages have been demonstrated. However, the role of these macrophages is unknown. The aims of this study are: 1) define the macrophage population in iLTS in the context of classically activated or M1 and M2 macrophage phenotypes, and 2) characterize the effect of monocyte-derived M1 and M2 macrophages on normal airway and LTS-derived fibroblasts (FBs) in vitro. STUDY DESIGN: Comparative analysis; in vitro controlled study. METHODS: Immunohistochemical analysis of human iLTS and control specimens was performed to define the macrophage population. In vitro, M1, and M2 macrophages were polarized using M-CSF + Interferon-gamma and lipopolysaccharide or Interleukin-4, respectively. FBs isolated from laryngotracheal scar (LTS-FBs) and normal tracheal airway (NA-FBs) in eight patients with iLTS were cocultured with polarized macrophages. Fibrosis gene expression, soluble collagen production, and proliferation were assessed. RESULTS: Immunohistochemical analysis revealed increased CD11b + cells (macrophage marker) in laryngotracheal scar specimens (18.3% vs. 8.5%, P = .03) and predominant CD206 (M2) costaining versus CD86 (M1) (51.5% vs. 9.8%, n = 10, P = .001). In vitro, NA-FBs cultured with M2 macrophages demonstrated a 2.41-fold increase in collagen-1 expression (P = .05, n = 8) and an increase in soluble collagen (9.98 vs. 8.875, mean difference: 1.11 95%, confidence interval 0.024-2.192, n = 8, P = .015). CONCLUSION: Increased populations of CD11b cells are present in iLTS specimens and are predominantly CD206+, indicating an M2 phenotype. In vitro, M2 macrophages promoted collagen expression in airway FBs. Targeting macrophages may represent a therapeutic strategy for attenuating fibrosis in iLTS. LEVEL OF EVIDENCE: NA Laryngoscope, 131:E346-E353, 2021.
OBJECTIVE: Macrophages exhibit distinct phenotypes and are dysregulated in a model of iatrogenic laryngotracheal stenosis (iLTS). Increased populations of alternatively activated or M2 macrophages have been demonstrated. However, the role of these macrophages is unknown. The aims of this study are: 1) define the macrophage population in iLTS in the context of classically activated or M1 and M2 macrophage phenotypes, and 2) characterize the effect of monocyte-derived M1 and M2 macrophages on normal airway and LTS-derived fibroblasts (FBs) in vitro. STUDY DESIGN: Comparative analysis; in vitro controlled study. METHODS: Immunohistochemical analysis of human iLTS and control specimens was performed to define the macrophage population. In vitro, M1, and M2 macrophages were polarized using M-CSF + Interferon-gamma and lipopolysaccharide or Interleukin-4, respectively. FBs isolated from laryngotracheal scar (LTS-FBs) and normal tracheal airway (NA-FBs) in eight patients with iLTS were cocultured with polarized macrophages. Fibrosis gene expression, soluble collagen production, and proliferation were assessed. RESULTS: Immunohistochemical analysis revealed increased CD11b + cells (macrophage marker) in laryngotracheal scar specimens (18.3% vs. 8.5%, P = .03) and predominant CD206 (M2) costaining versus CD86 (M1) (51.5% vs. 9.8%, n = 10, P = .001). In vitro, NA-FBs cultured with M2 macrophages demonstrated a 2.41-fold increase in collagen-1 expression (P = .05, n = 8) and an increase in soluble collagen (9.98 vs. 8.875, mean difference: 1.11 95%, confidence interval 0.024-2.192, n = 8, P = .015). CONCLUSION: Increased populations of CD11b cells are present in iLTS specimens and are predominantly CD206+, indicating an M2 phenotype. In vitro, M2 macrophages promoted collagen expression in airway FBs. Targeting macrophages may represent a therapeutic strategy for attenuating fibrosis in iLTS. LEVEL OF EVIDENCE: NA Laryngoscope, 131:E346-E353, 2021.
Authors: Nadezhda Glezeva; Victor Voon; Chris Watson; Stephen Horgan; Kenneth McDonald; Mark Ledwidge; John Baugh Journal: J Card Fail Date: 2014-11-18 Impact factor: 5.712
Authors: Vlad C Sandulache; J Brett Chafin; Ha-Sheng Li-Korotky; Todd D Otteson; Joseph E Dohar; Patricia A Hebda Journal: Arch Otolaryngol Head Neck Surg Date: 2007-04
Authors: Isabelle Y Liu; Abie H Mendelsohn; Harry Ching; Jennifer Long; Dinesh K Chhetri; Gerald S Berke Journal: JAMA Otolaryngol Head Neck Surg Date: 2015-03 Impact factor: 6.223
Authors: Jonas Christian Schupp; Harald Binder; Benedikt Jäger; Giuseppe Cillis; Gernot Zissel; Joachim Müller-Quernheim; Antje Prasse Journal: PLoS One Date: 2015-01-15 Impact factor: 3.240
Authors: Alexander Gelbard; Nicolas-George Katsantonis; Masanobu Mizuta; Dawn Newcomb; Joseph Rotsinger; Bernard Rousseau; James J Daniero; Eric S Edell; Dale C Ekbom; Jan L Kasperbauer; Alexander T Hillel; Liying Yang; C Gaelyn Garrett; James L Netterville; Christopher T Wootten; David O Francis; Charles Stratton; Kevin Jenkins; Tracy L McGregor; Jennifer A Gaddy; Timothy S Blackwell; Wonder P Drake Journal: Laryngoscope Date: 2016-06-14 Impact factor: 3.325
Authors: Shweta Joshi; Alok R Singh; Simon S Wong; Muamera Zulcic; Min Jiang; Annie Pardo; Moises Selman; James S Hagood; Donald L Durden Journal: PLoS One Date: 2017-08-17 Impact factor: 3.752
Authors: Cininta Savitri; Jae Won Kwon; Valeryia Drobyshava; Sang Su Ha; Kwideok Park Journal: Tissue Eng Regen Med Date: 2021-12-28 Impact factor: 4.451
Authors: Ilaha Isali; Phillip McClellan; Thomas R Wong; Snigdha Cingireddi; Mukesh Jain; James M Anderson; Adonis Hijaz; Ozan Akkus Journal: Tissue Eng Part A Date: 2022-07-26 Impact factor: 4.080